loader

nyse:pfe

LATEST ARTICLES
Pharmaceutical Investing

PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

Pharmaceutical Investing

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Pharmaceutical Investing

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

Pharmaceutical Investing

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

Pharmaceutical Investing

Pfizer Completes Licensing Agreement with 3SBio

Pharmaceutical Investing

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Pharmaceutical Investing

Pfizer Declares Third-Quarter 2025 Dividend

Pharmaceutical Investing

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

Pharmaceutical Investing

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Pharmaceutical Investing

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Pharmaceutical Investing

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Pharmaceutical Investing

Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Latest News

More News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES